Oxford Biomedica (LON:OXB) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Oxford Biomedica plc (LON:OXB) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 617.71 and traded as low as GBX 501. Oxford Biomedica shares last traded at GBX 512, with a volume of 12,360,560 shares changing hands.

Analyst Ratings Changes

Several brokerages recently issued reports on OXB. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Royal Bank Of Canada dropped their price objective on shares of Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating on the stock in a research note on Monday, August 10th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Oxford Biomedica to a “hold” rating and cut their price objective for the stock from GBX 800 to GBX 595 in a report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

Oxford Biomedica Stock Performance

The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The business has a 50 day moving average price of GBX 574.58 and a 200 day moving average price of GBX 615.40. The stock has a market capitalization of £637.86 million, a PE ratio of -19.58 and a beta of 1.10.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.